Retail giant Cotton On has hit back at allegations of copyright infringement, highlighting the prevalence of copying in the fashion industry.
A patent holding company has won its legal dispute with a rival over biometric security patents the subject of an infringement case against Apple.
Apple has fired back in a lawsuit alleging its iPhone and iPad devices equipped with Touch ID and Face ID technology infringe patents held by an Australian non-practicing entity, hitting the company with its own case claiming the patents are invalid.
A judge has recused himself from hearing a dispute over the alleged infringement of the copyright for the disco classic ‘Love Is In the Air’ on the eve of a damages hearing.
Burger giant Hungry Jack’s has lost its bid to have McDonald’s hand over test results showing the “pre-cooked” weight of its Big Mac beef patties, with a judge finding they were not relevant to whether the rival’s Big Jack burger had 25 per cent “more Aussie beef”.
The Full Federal Court has shot down plumbing company Repipe’s appeal of a decision rejecting its innovation patents for a claimed computer-implemented invention, saying it only addressed issues in business operations rather than improving on computer technology.
Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.
Tech company Vehicle Management Systems has come up short in its third attempt to block competitor SARB Management Group’s patent application for a magnetic parking overstay detector, with the Full Court rejecting claims that VMS’ managing director should have been listed as the device’s inventor.
Coffee giant Vittoria has lost its bid to register the trade mark “Victoria Coffee”, with IP Australia finding the mark could prevent other businesses from honestly describing coffee products by referring to the state of Victoria.
Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer drug Revlimid in Australia.